.

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ALDARA Drug Profile

« Back to Dashboard
Aldara is a drug marketed by Medicis and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ALDARA is imiquimod. There are thirteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the imiquimod profile page.

Summary for Tradename: ALDARA

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2

Pharmacology for Tradename: ALDARA

Clinical Trials for: ALDARA

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis
ALDARA
imiquimod
CREAM;TOPICAL020723-001Feb 27, 1997RXYes7,696,159*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALDARA

These historical archives are available as an add-on to one-year subscriptions.
See the Signup Form for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Medicis
ALDARA
imiquimod
CREAM;TOPICAL020723-001Feb 27, 19974,689,338*PED<disabled>
Medicis
ALDARA
imiquimod
CREAM;TOPICAL020723-001Feb 27, 19975,238,944*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: ALDARA

Drugname Dosage Strength RLD Submissiondate
imiquimodCream5%Aldara10/17/2006
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

`abc